EQUITECH-BIO, INC.

EQUITECH-BIO, INC. specializes in biopharmaceutical manufacturing and process development within the federal contract landscape, leveraging its expertise in 325414 — Pharmaceutical Preparation Manufacturing. The company focuses on the scalable production of active pharmaceutical ingredients, sterile fill-finish operations, and analytical method validation to support government health and defense initiatives. Technical capabilities include GMP compliance, aseptic processing, bioreactor system optimization, and quality control systems aligned with FDA and USP standards. Their operational approach emphasizes process robustness, batch traceability, and regulatory documentation integrity, positioning them as a reliable partner for mission-critical biologics and vaccine production needs. No agency relationships can be inferred from available award data, and no recent contract awards are documented to illustrate specific program engagements. As such, direct ties to federal departments such as HHS, DoD, or BARDA cannot be confirmed. The contractor’s primary industry focus is pharmaceutical manufacturing, with operational emphasis on small-molecule and biologic drug substance production. Their market positioning centers on niche, high-compliance manufacturing services for government-funded biodefense, pandemic preparedness, and medical countermeasure programs, though specific vertical applications remain unverified due to lack of public award history. EQUITECH-BIO, INC. is structured as a small business under the 2L entity classification and is headquartered in Kerrville, Texas. The company holds no formal government certifications such as 8(a), HUBZone, or WOSB, and its geographic footprint is limited to its Texas facility. While its technical capabilities align with federal biomanufacturing demands, its public market presence is constrained by the absence of disclosed contract performance data.